Literature DB >> 3114349

Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.

H S Mueller, A K Rao, S A Forman.   

Abstract

Coronary recanalization rates and changes in plasma proteins of the fibrinolytic system were evaluated with two preparations of recombinant tissue-type plasminogen activator (rt-PA): the early formulation in liquid excipient ("old" rt-PA) and the later lyophilized form ("new" rt-PA). The dose dependency of coronary recanalization and of effects on plasma proteins was evaluated for the new rt-PA. Four groups of patients were studied: Study 1, 80 mg old rt-PA infused intravenously over 3 hours (n = 113); Study A, 80 mg new rt-PA over 3 hours (n = 47); Study B, 100 mg new rt-PA over 3 hours (n = 83); and Study C, 150 mg new rt-PA over 6 hours (n = 62). With equal doses of 80 mg, coronary recanalization rates at 90 minutes of infusion, determined angiographically, averaged 62% (Study 1) and 45% (Study A) with no overlap of 95% confidence limits. Increasing the dose of the new rt-PA to 100 mg, recanalization rates at 90 minutes averaged 71% (Study B), similar to those observed in Study 1. An increase to 150 mg resulted in higher recanalization rates at 30 minutes of infusion, 42% compared with 24% in Study 1 with no overlap of 95% confidence limits, and comparable rates at 90 minutes, 76 versus 62%. A linear trend test indicated a significant relation (p less than 0.01) between the dose of the new rt-PA and the rate of coronary recanalization at 30, 60 and 90 minutes of infusion. The new rt-PA affected plasma proteins of the fibrinolytic system less than the old form. There was a dose-dependent relation (p less than 0.001) in the effect of the new rt-PA on the plasma proteins. The frequency of bleeding complications was similar in the four study groups. These results indicate that the new rt-PA is less potent than the old rt-PA, in relation to both coronary reperfusion and systemic fibrinogenolysis. A higher and longer dosage regimen caused more rapid recanalization with similar effects on fibrinogenolysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114349     DOI: 10.1016/s0735-1097(87)80188-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

1.  Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 2.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

3.  Thrombolysis with low dose tissue plasminogen activator.

Authors:  E Doyle; J Britto; J Freeman; F Munro; N S Morton
Journal:  Arch Dis Child       Date:  1992-12       Impact factor: 3.791

4.  Thrombolysis with streptokinase during cardiopulmonary resuscitation: a single center experience and review of the literature.

Authors:  Farid Aliyev; Mohammed Habeb; Erhan Babalik; Bilgehan Karadag
Journal:  J Thromb Thrombolysis       Date:  2005-12       Impact factor: 2.300

Review 5.  Thrombolysis. An approach still on the move.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

6.  Early Acute Ischemic Stroke Management for Pharmacists.

Authors:  Michael Armahizer; Alison Blackman; Michael Plazak; Gretchen M Brophy
Journal:  Hosp Pharm       Date:  2018-08-07

7.  Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients.

Authors:  P Gibelin; F Tiger; V Moles; S Bossan; P Blanc; M Baudouy; P Morand
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

8.  Clinical experience with alteplase in the management of intracardiac and major cardiac vessels thrombosis in pediatrics: a case series.

Authors:  Abdulrazaq S Al-Jazairi; Roaa A Al-Gain; Zead R Bulbul; Antoine J Cherfan
Journal:  Ann Saudi Med       Date:  2010 May-Jun       Impact factor: 1.526

9.  A prospective, randomized, blinded, and placebo-controlled trial of intraoperative intra-arterial urokinase infusion during lower extremity revascularization. Regional and systemic effects.

Authors:  A J Comerota; A K Rao; R C Throm; C I Skibinski; G J Beck; S Ghosh; L Sun; G R Curl; J J Ricotta; R A Graor
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

Review 10.  New strategies in the development of thrombolytic agents.

Authors:  H R Lijnen; D Collen
Journal:  Blut       Date:  1988-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.